| |
| |
| Exchange: |
Nasdaq National Market |
| Security
Type: |
Common |
| Shares
Out: |
20,430,000 |
| Market
Cap: |
1.37(B) |
| Last
Volume: |
2,387,520 |
Avg
Vol: |
2,380,888 |
| 52
Week Range: |
$38.04 - $69.69 |
|
| Level
I Sector: |
Health Care |
| Level
II Sector: |
Drugs |
| Level
III Sector: |
Biotechnology |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile ANI Pharmaceuticals is a bio-pharmaceutical company focused on developing, manufacturing, and marketing branded and generic prescription pharmaceuticals. Co.'s products include: Candesartan Hydrochlorothiazide, Fenofibrate, Fluvoxamine, Hydrocortisone Enema, Lithium Carbonate ER, Mesalamine, Propranolol ER, Terbutaline, and Vancomycin.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
0 |
0 |
| Total Buy Value |
$0 |
$0 |
$0 |
$0 |
| Total People Bought |
0 |
0 |
0 |
0 |
| Total Buy Transactions |
0 |
0 |
0 |
0 |
| Total Shares Sold |
219,404 |
449,536 |
1,210,262 |
1,558,328 |
| Total Sell Value |
$13,995,768 |
$28,694,676 |
$72,583,660 |
$87,706,653 |
| Total People Sold |
8 |
10 |
12 |
12 |
| Total Sell Transactions |
23 |
44 |
86 |
98 |
| End Date |
2024-04-04 |
2024-01-02 |
2023-07-04 |
2022-07-04 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Gassert Chad |
SVP - CORP. DEV. & STRATEGY |
• – – |
2024-07-01 |
4 |
AS |
$63.44 |
$1,268,800 |
I/I |
(20,000) |
193,226 |
|
- |
|
| Shanmugam Muthusamy |
HEAD OF R&D, COO-NOVITIUM OPS |
• • – |
2024-06-21 |
4 |
AS |
$58.90 |
$1,178,000 |
I/I |
(20,000) |
682,620 |
|
- |
|
| Shanmugam Muthusamy |
HEAD OF R&D, COO-NOVITIUM OPS |
• • – |
2024-06-20 |
4 |
AS |
$59.86 |
$685,217 |
I/I |
(11,447) |
702,620 |
|
- |
|
| Shanmugam Muthusamy |
HEAD OF R&D, COO-NOVITIUM OPS |
• • – |
2024-06-18 |
4 |
AS |
$60.76 |
$644,481 |
I/I |
(10,607) |
714,067 |
|
- |
|
| Shanmugam Muthusamy |
HEAD OF R&D, COO-NOVITIUM OPS |
• • – |
2024-06-17 |
4 |
AS |
$61.41 |
$487,964 |
I/I |
(7,946) |
724,674 |
|
- |
|
| Cook Meredith |
SR. VP, GENERAL COUNSEL & SEC. |
• – – |
2024-06-13 |
4 |
AS |
$63.80 |
$15,950 |
D/D |
(250) |
59,231 |
|
- |
|
| Marken James G. |
SVP OPS & PROD DEV |
• – – |
2024-06-07 |
4 |
D |
$67.70 |
$750,590 |
D/D |
(11,087) |
117,829 |
|
- |
|
| Marken James G. |
SVP OPS & PROD DEV |
• – – |
2024-06-07 |
4 |
OE |
$49.51 |
$661,366 |
D/D |
12,550 |
128,916 |
|
- |
|
| Gutwerg Ori |
SVP, GENERICS |
• – – |
2024-06-05 |
4 |
S |
$67.00 |
$199,995 |
D/D |
(2,985) |
77,227 |
|
- |
|
| Carey Stephen P. |
SVP & CFO |
• – – |
2024-06-04 |
4 |
S |
$63.58 |
$317,900 |
D/D |
(5,000) |
161,968 |
|
- |
|
| Gassert Chad |
SVP - CORP. DEV. & STRATEGY |
• – – |
2024-06-03 |
4 |
AS |
$64.41 |
$1,288,200 |
I/I |
(20,000) |
213,226 |
|
- |
|
| Mutz Christopher |
HEAD OF RARE DISEASE |
• – – |
2024-05-21 |
4 |
S |
$61.61 |
$123,220 |
D/D |
(2,000) |
83,277 |
|
- |
|
| Pera Antonio R |
Director |
– • – |
2024-05-21 |
4 |
A |
$0.00 |
$0 |
D/D |
4,410 |
31,037 |
|
- |
|
| Leonard Matthew J |
Director |
– • – |
2024-05-21 |
4 |
A |
$0.00 |
$0 |
D/D |
4,410 |
11,993 |
|
- |
|
| Walsh Patrick D |
Director |
– • – |
2024-05-21 |
4 |
A |
$0.00 |
$0 |
D/D |
4,410 |
74,712 |
|
- |
|
| Thoma Jeanne |
Director |
– • – |
2024-05-21 |
4 |
A |
$0.00 |
$0 |
D/D |
4,410 |
40,609 |
|
- |
|
| Haughey Thomas |
Director |
– • – |
2024-05-21 |
4 |
A |
$0.00 |
$0 |
D/D |
4,410 |
51,526 |
|
- |
|
| Tannenbaum Renee P |
Director |
– • – |
2024-05-21 |
4 |
A |
$0.00 |
$0 |
D/D |
4,410 |
22,621 |
|
- |
|
| Shanmugam Muthusamy |
HEAD OF R&D, COO-NOVITIUM OPS |
• • – |
2024-05-20 |
4 |
AS |
$61.81 |
$794,568 |
I/I |
(12,855) |
732,620 |
|
- |
|
| Shanmugam Muthusamy |
HEAD OF R&D, COO-NOVITIUM OPS |
• • – |
2024-05-17 |
4 |
AS |
$62.09 |
$362,357 |
I/I |
(5,836) |
745,475 |
|
- |
|
| Tannenbaum Renee P |
Director |
– • – |
2024-05-16 |
4 |
S |
$63.87 |
$127,740 |
D/D |
(2,000) |
18,211 |
|
- |
|
| Shanmugam Muthusamy |
HEAD OF R&D, COO-NOVITIUM OPS |
• • – |
2024-05-16 |
4 |
AS |
$63.84 |
$1,050,743 |
I/I |
(16,459) |
751,311 |
|
- |
|
| Shanmugam Muthusamy |
HEAD OF R&D, COO-NOVITIUM OPS |
• • – |
2024-05-15 |
4 |
AS |
$65.86 |
$978,021 |
I/I |
(14,850) |
767,770 |
|
- |
|
| Lalwani Nikhil |
PRESIDENT & CEO |
• • – |
2024-05-14 |
4 |
S |
$66.10 |
$1,101,821 |
D/D |
(16,669) |
377,505 |
|
- |
|
| Cook Meredith |
SR. VP, GENERAL COUNSEL & SEC. |
• – – |
2024-05-13 |
4 |
AS |
$67.69 |
$16,923 |
D/D |
(250) |
59,481 |
|
- |
|
417 Records found
|
|
Page 1 of 17 |
|
|
0.14 (0.21%) 
